Related references
Note: Only part of the references are listed.Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis
Yosuke Nakagawa et al.
KIDNEY INTERNATIONAL (2020)
Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
Annelies De Mare et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Sclerostin is not associated with cardiovascular event or fracture in kidney transplantation candidates
Hanne Skou Jorgensen et al.
CLINICAL NEPHROLOGY (2018)
Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy
Syazrah Salam et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease
Daniel Cejka et al.
KIDNEY INTERNATIONAL (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy
Sharon M. Moe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Bone Mineral Density and Serum Biochemical Predictors of Bone Loss in Patients with CKD on Dialysis
Hartmut H. Malluche et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Relationship Between Serum Sclerostin, Bone Metabolism Markers, and Bone Mineral Density in Maintenance Hemodialysis Patients
Eiji Ishimura et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients
Mehmet Kanbay et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Renal Elimination of Sclerostin Increases With Declining Kidney Function
Daniel Cejka et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Sclerostin Blood Levels Before and After Kidney Transplantation
Marco Bonani et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2014)
High rates of death and hospitalization follow bone fracture among hemodialysis patients
Francesca Tentori et al.
KIDNEY INTERNATIONAL (2014)
The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD
Solenne Pelletier et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Increased risk of hip fracture among Japanese hemodialysis patients
Minako Wakasugi et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2013)
Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study
P. Garnero et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy
Yves Sabbagh et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Serum Sclerostin and Risk of Hip Fracture in Older Caucasian Women
Aarthi Arasu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients
Daniel Cejka et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide
S. A. Polyzos et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered
A. Moustafa et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Sclerostin and Dickkopf-1 in Renal Osteodystrophy
Daniel Cejka et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men
Ulrike I. Moedder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays
Melissa McNulty et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Asiri R. Wijenayaka et al.
PLOS ONE (2011)
Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways
Carola Krause et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin
Alexander G. Robling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study
M. Jadoul et al.
KIDNEY INTERNATIONAL (2006)
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
T Bellido et al.
ENDOCRINOLOGY (2005)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation
DA Glass et al.
DEVELOPMENTAL CELL (2005)
Increased risk of hip fracture among patients with end-stage renal disease
AM Alem et al.
KIDNEY INTERNATIONAL (2000)